Horizon Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HORIZON PHARMA, and when can generic versions of HORIZON PHARMA drugs launch?
HORIZON PHARMA has one approved drug.
There are twelve US patents protecting HORIZON PHARMA drugs.
There are forty-nine patent family members on HORIZON PHARMA drugs in thirty-three countries and ten supplementary protection certificates in nine countries.
Summary for Horizon Pharma
| International Patents: | 49 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Horizon Pharma: | See patent lawsuits for Horizon Pharma |
Drugs and US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | 9,233,077*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | 9,925,157 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | 10,548,859 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Horizon Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2535044 | See Plans and Pricing |
| European Patent Office | 1919458 | See Plans and Pricing |
| Portugal | 1919458 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Horizon Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1919458 | 122014000023 | Germany | See Plans and Pricing | PRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906 |
| 1919458 | SPC/GB14/019 | United Kingdom | See Plans and Pricing | PRODUCT NAME: CYSTEAMINE; REGISTERED: UK EU/1/13/861 20130910 |
| 1919458 | C 2014 012 | Romania | See Plans and Pricing | PRODUCT NAME: CISTEAMINABITARTRAT; NATIONAL AUTHORISATION NUMBER: EU/1/13/861; DATE OF NATIONAL AUTHORISATION: 20130906; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/861; DATE OF FIRST AUTHORISATION IN EEA: 20130906 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
